Back to search results

VHB937 for Early Alzheimer's Disease

This study is testing a treatment called VHB937 in people with early Alzheimer's disease. Researchers want to see if VHB937 is safe and if it can help with memory and thinking abilities. You may be able to join if you are between 50 and 85 years old and have been diagnosed with mild cognitive impairment (MCI) due to Alzheimer's or mild Alzheimer's. Your Alzheimer's diagnosis will need to be confirmed by spinal fluid tests or a special brain scan (amyloid PET imaging). The main way researchers will know if VHB937 is successful is by looking at changes in your thinking abilities over 72 weeks using a tool called the Clinical Dementia Rating scale. The study is currently unclear on its recruitment status and plans to enroll 407 participants.

Study design
This is a Phase II study that is randomized, double-blind (meaning neither you nor your doctor will know if you're receiving VHB937 or a placebo), and placebo-controlled. It plans to enroll 407 participants.
What's involved
You would participate in the double-blind part of the study for 72 weeks, followed by an extension. You will need a reliable study partner to accompany you to visits.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for 72 weeks during the double-blind part of the study, with an extension period afterward.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07094516

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Recruiting
PHASE2Ages 50–85InterventionalTreatment
Novartis Pharmaceuticals
~407 participants
Updated 2026-06-26 on ClinicalTrials.gov
What's tested:VHB937Placebo

At a glance

Recruiting sites
74 of 74 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in the Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)
Measured over Baseline and Week 72

Conditions

Alzheimer's Disease

Explore related trials

Alzheimer's DiseaseAmyloid

Where it's being run

74 sites across 42 states
Florida9
United Kingdom7
Ontario5
California3
Tokyo3
Poland3
South Korea3
New South Wales2

Who to contact

Novartis Pharmaceuticals
[email protected]
1-888-669-6682
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female participants 50 to 85 years of age
Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD
Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0
Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging
Reliable study partner who can accompany the participant at study visits
If on symptomatic AD treatment (AChEIs/memantine), on a stable dose prior to starting study treatment

Exclusion

Dementia due to a condition other than AD, including but not limited to, frontal temporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington disease, vascular dementia.
History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study
Transient ischemic attacks (TIA) or stroke occurring within 12 months
Clinical evidence of liver or renal disease/injury
Current major depressive episode that is not adequately controlled, history of schizophrenia, other chronic psychosis
Significant neurological disease other than dementia (e.g. serious brain infection, traumatic brain injury, multiple concussions, epilepsy or recurrent seizures
Presence of suicidal ideation within 6 months or suicidal behavior within 2 years before Screening
Presence of cancer, HIV, Hep B, Hep C, uncontrolled thyroid disease, uncontrolled diabetes
Taking any prohibited medications

What this trial measures

  • Change from Baseline in the Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)Baseline and Week 72

    The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care. Based on in-depth semi-structured interview, each domain is assigned a score, which is summed to obtain the Sum of Boxes (SB) score, ranging from 0 to 18 with higher scores indicating worse condition